Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963078 | 1.00 | GPR119 (0.43) | GPR119SSTR4NR1H2HDAC4USP2 | |
| SCHEMBL12836236 | 1.00 | GPR119 (0.43) | GPR119SSTR4NR1H2HDAC4USP2 | |
| SCHEMBL1769141 | 0.86 | GPR119 (0.45) | GPR119NR1H2HDAC4USP2SMN1; SMN2 | |
| SCHEMBL9963086 | 0.85 | HCRTR1 (0.39) | SSTR4NR1H2HDAC4USP2SMN1; SMN2 | |
| SCHEMBL9965945 | 0.85 | HCRTR1 (0.39) | SSTR4NR1H2HDAC4USP2SMN1; SMN2 | |
| SCHEMBL12836455 | 0.85 | HCRTR1 (0.39) | SSTR4NR1H2HDAC4USP2SMN1; SMN2 | |
| SCHEMBL9965905 | 0.84 | NR1H2 (0.36) | GPR119SSTR4NR1H2HDAC4SMN1; SMN2 | |
| SCHEMBL9963084 | 0.84 | NR1H2 (0.36) | GPR119SSTR4NR1H2HDAC4SMN1; SMN2 | |
| SCHEMBL22194373 | 0.83 | GPR119 (0.39) | GPR119SSTR4NR1H2HDAC4USP2 | |
| SCHEMBL22194627 | 0.83 | GPR119 (0.39) | GPR119SSTR4NR1H2HDAC4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | GPR119 188/4885SSTR4 462/4885NR1H2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.